Background Venetoclax combined with intensive chemotherapy has been shown to be safe
with promising activity in fit patients with newly diagnosed acute myeloid leukaemia. The aim …

Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a globally
poor outcome, especially in patients ineligible for intensive chemotherapy. Until recently …

This analysis represents the longest‐term follow‐up for patients with acute myeloid leukemia
(AML) treated with 400 mg of venetoclax plus azacitidine or decitabine. Adults with newly …

Combinations of the BCL‐2 inhibitor, venetoclax, with either hypomethylating agents (HMA)
or low dose cytarabine (LDAC), have shown promising results in clinical trials of AML …

Venetoclax (ven) plus azacitidine (aza) is the standard of care for patients with newly
diagnosed acute myeloid leukemia (AML) who are not candidates for intensive …

PURPOSE Effective treatment options are limited for patients with acute myeloid leukemia
(AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study …

Background: Multiple studies have demonstrated the modest efficacy of low-dose cytarabine
(LDAC) in older patients (≥ 65 years) with Acute Myeloid Leukemia (AML) who are unlikely …

Simple Summary The use of venetoclax combined with hypomethylating agents or low-dose
cytarabine in patients with newly diagnosed acute myeloid leukemia unfit for intensive …

Hypomethylating agents (HMA) with venetoclax is a new standard for older/unfit patients
with acute myeloid leukemia (AML). However, it is unknown how HMA with venetoclax …

Venetoclax in combination with intensive therapies is explored in both the upfront and
relapse/refractory (R/R) setting, and available data suggest that such regimens are effective …